OCGN Jan 2024 12.500 put
| Previous close | 10.46 |
| Open | 10.50 |
| Bid | 8.00 |
| Ask | 12.80 |
| Strike | 12.50 |
| Expiry date | 2024-01-19 |
| Day's range | 10.40 - 10.50 |
| Contract range | N/A |
| Volume | |
| Open interest | 43 |
GlobeNewswireOcugen CEO to Present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
MALVERN, Pa., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder will present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL—taking
Insider MonkeyOcugen, Inc. (NASDAQ:OCGN) Q3 2023 Earnings Call Transcript
Ocugen, Inc. (NASDAQ:OCGN) Q3 2023 Earnings Call Transcript November 9, 2023 Ocugen, Inc. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.08. Operator: Good morning and welcome to Ocugen’s Third Quarter 2023 Financial Results and Business Update. Please note that this call is being recorded at this time. All participants’ line are in a […]
- GlobeNewswire
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease
MALVERN, Pa., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the first patient has been dosed in its Phase 1/2 GARDian clinical trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease, a rare genetically inherited disease that directly affects the ret
